

150 1644

• I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Sept 27, 2005

By: [Signature]



PATENT  
Attorney Docket No.: 020093-000810US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Michael L. Salgaller, et al.

Application No.: 09/854,248

Filed: May 11, 2001

For: METHOD TO INCREASE  
CLASS I PRESENTATION OF  
EXOGENOUS ANTIGENS BY  
HUMAN DENDRITIC CELLS

Customer No. 20350

Confirmation No.: 7931

Examiner: Gerald R. Ewoldt

Art Unit: 1644

**INFORMATION DISCLOSURE  
STATEMENT UNDER  
37 CFR §1.97 and §1.98**

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the foreign patent documents Cite Nos. AA-AD and non-patent literature documents Cite Nos. AE-AI are enclosed herewith.

Also enclosed is a copy of the Supplementary European Search Report corresponding to the European application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

**CERTIFICATION**

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Date: 27 September 2005

By: Brian W. Poor  
Brian W. Poor  
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 206-467-9600  
Fax: 415-576-0300  
BWP:mmm



PTO/SB/21 (09-04)

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/854,248
Filing Date	May 11, 2001
First Named Inventor	Salgaller, Michael L.
Art Unit	1644
Examiner Name	Gerald R. Ewoldt
Attorney Docket Number	020093-000810US

**ENCLOSURES (Check all that apply)**

- ☐ Fee Transmittal Form  
☐ Fee Attached  
☐ Amendment/Reply  
☐ After Final  
☐ Affidavits/declaration(s)  
☐ Extension of Time Request  
☐ Express Abandonment Request  
☒ Information Disclosure Statement

- ☐ Certified Copy of Priority Document(s)  
☐ Reply to Missing Parts/ Incomplete Application  
☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)  
☐ Licensing-related Papers  
☐ Petition  
☐ Petition to Convert to a Provisional Application  
☐ Power of Attorney, Revocation  
Change of Correspondence Address  
☐ Terminal Disclaimer  
☐ Request for Refund  
☐ CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD

- ☐ After Allowance Communication to TC  
☐ Appeal Communication to Board of Appeals and Interferences  
☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  
☐ Proprietary Information  
☐ Status Letter  
☒ Other Enclosure(s) (please identify below):  
Form PTO/SB/08A (1 pg.);  
Form PTO/SB/08B (1 pg.);  
Copy of Supplemental European Search Report (6 pgs.);  
References AA-AI (9); and  
Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Townsend and Townsend and Crew LLP
Signature	<i>Brian W. Poor</i>
Printed name	Brian W. Poor
Date	27 September 2005

Reg. No. 32,928

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

*J. M. Smolen*  
J. M. Smolen

Date

Sept. 27, 2005



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Substitute for form 1449A/PTO</b>			
		<b>Complete if Known</b>			
		Application Number	09/854,248		
		Filing Date	May 11, 2001		
		First Named Inventor	Salgaller, Michael L.		
		Art Unit	1644		
Sheet	1	of	2	Examiner Name	Gerald R. Ewoldt
				Attorney Docket Number	020093-000810US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AA	PCT	WO 94/20127		09/15/1994	Cytel Corporation		<input type="checkbox"/>
	AB	PCT	WO 97/04802		02/13/1997	Pacific Northwest Cancer Foundation		<input type="checkbox"/>
	AC	PCT	WO 00/06723		02/10/2000	Yeda Research and Development Company Ltd. at the Weizmann Institute of Science		<input type="checkbox"/>
	AD	PCT	WO 01/00225		01/04/2001	Epimmune Inc.		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
60592310 v1



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/854,248		
		Filing Date	May 11, 2001		
		First Named Inventor	Salgaller, Michael L.		
		Art Unit	1644		
		Examiner Name	Gerald R. Ewoldt		
Sheet	2	of	2	Attorney Docket Number	020093-000810US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AE	HARRIS, D. <i>et al.</i> , "Immunological approaches to the treatment of prostate cancer," <i>Semin. Oncol.</i> , 26:439-447 (August 1999).	
	AF	KAUFMANN, S. and HESS, J., "Impact of intracellular location of and antigen display by intracellular bacteria: Implications for vaccine development," <i>Immunol. Lett.</i> , 65:81-84 (January 1999).	
	AG	KLAGGE, I. <i>et al.</i> , "Granulocyte-macrophage colony-stimulating factor elevates invariant chain expression in immature myelomonocytic cell lines," <i>Immunology</i> , 91:114-120 (1997).	
	AH	STOVER, C.K. <i>et al.</i> , "New use of BCG for recombinant vaccines," <i>Nature</i> , 351:456-460 (June 6, 1991).	
	AI	ZEOLI, C. <i>et al.</i> , "Expression of prostate specific molecules in BCG: A potential immunotherapeutic vaccine," Proceedings of the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 1-5, 2000, <i>Proc. Am. Assoc. Cancer Res.</i> , 41:875 (April 1, 2001).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.